Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs General Motors Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while General Motors Company trades at $78.35 (market cap $70.19B). The key difference: General Motors Company is the larger of the two by market cap, and General Motors Company pays a 0.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GM | |
|---|---|---|
Market Cap | $39.89B | $70.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $86.38 |
52-Week Low | $278.09 | $48.89 |
Enterprise Value | $38.15B | $173.53B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
General Motors (GM) trades at $77.85, up 1.57% with a bearish technical signal despite three consecutive quarterly earnings beats. The company maintains strong cash flow generation ($26.9B operating cash flow in 2025) and trades at discounted valuations (P/S 0.4, P/B 1.12). Recent news highlights GM's strategic pivot into energy and battery technology partnerships as automotive sales face industry headwinds.
GM presents a value opportunity with analyst consensus price target of $100.27 (29% upside) but faces execution risks in EV transition and margin pressure. The stock's outlook depends on Q2 earnings delivering clean cash flow and sustained margin improvement amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
